Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
About this trial
This is an interventional treatment trial for Stomach Cancer focused on measuring Stomach cancer, Adjuvant chemotherapy, Mitomycin, Cisplatin, Doxifluridine
Eligibility Criteria
Inclusion Criteria: Pathologically proven gastric adenocarcinoma Curative resection was done stage II, IIIA, IIIB, IV (including T4, lesions or N3, but excluding M1 lymph node metastasis) age: 18-69 years old Performance status: ECOG 0-2 Adequate bone marrow function (WBC ≥ 4,000/ul, platelet count ≥ 100,000/ul, hemoglobin ≥ 10 g/dl) Adequate renal function (serum creatinine≤ 1.5) Adequate liver function (serum bilirubin ≤1.5 mg/dl, AST/ALT ≤ 3 x normal upper limit) Written informed consent was signed by the patient Exclusion Criteria: Previous chemotherapy or radiotherapy Active ongoing infection which antibiotic treatment is needed Pregnant or lactating women Psychosis or convulsion disorder Ascites in preoperative abdomen CT Systemic disease which interfere the administration of chemotherapy Previous history of other malignancy except cured non-malignant skin cancer and uterine cervical cancer in situ
Sites / Locations
- Asan Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Mitomycin and doxifluridine
Mitomycin, doxifluridine and cisplatin
Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)